A cross-sectional analysis of treatment patterns in small-cell lung cancer in five European countries
Name:
reguart-et-al-2023-a-cross-sec ...
Size:
1.630Mb
Format:
PDF
Description:
Found with Open Access Button
Authors
Reguart, N.Pérol, M.
Cortinovis, D.
Puntis, S.
Öhrling, K.
Archangelidi, O.
Louie, K. S.
Blackhall, Fiona
Sebastian, M.
Affiliation
The Christie NHS Foundation Trust, Manchester, UK.Issue Date
2023
Metadata
Show full item recordAbstract
Aim: To investigate changes in treatment patterns in extensive-stage small-cell lung cancer (ES-SCLC) in France, Germany, Italy, Spain and the UK (EU5) between 2018 and 2021. Methods: Cross-sectional data from an oncology database were analyzed retrospectively. Results: Of 5832 eligible patients, 88.4% had stage IV disease at diagnosis. Among patients receiving first-line treatment, 91.8% (1079 /1176) received the platinum-etoposide (PE) combination in 2018 which decreased to 42.3% (509/1203) by 2021. Usage of the PE-atezolizumab combination increased from 0 to 41.2% during the same timeframe. Topotecan monotherapy remained the most widely used second-line treatment regardless of patients' platinum sensitivity. Conclusion: The first-line standard of care for ES-SCLC has evolved in EU5 with the PE-atezolizumab/durvalumab combination gradually superseding PE usage.Citation
Reguart N, Pérol M, Cortinovis D, Puntis S, Öhrling K, Archangelidi O, et al. A cross-sectional analysis of treatment patterns in small-cell lung cancer in five European countries. Future oncology (London, England). 2023 Nov 30. PubMed PMID: 38031886. Epub 2023/11/30. eng.Journal
Future OncologyDOI
10.2217/fon-2022-1315PubMed ID
38031886Additional Links
https://dx.doi.org/10.2217/fon-2022-1315Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.2217/fon-2022-1315
Scopus Count
Collections
Related articles
- Comparison of Real-world Efficacy and Safety of Atezolizumab and Durvalumab in Combination With Chemotherapy for First-line Treatment of Extensive-stage Small-cell Lung Cancer.
- Authors: Igata F, Inoue H, Ikeda T, Nakao A, Ebi N, Fujita M
- Issue date: 2024 Jul
- Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
- Authors: Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Każarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L, CASPIAN investigators
- Issue date: 2021 Jan
- Real-world evaluation of first-line treatment of extensive-stage small-cell lung cancer with atezolizumab plus platinum/etoposide: a focus on patients with brain metastasis.
- Authors: Chen H, Ma X, Liu J, Yang Y, He Y, Fang Y, Wang L, Fang J, Zhao J, Zhuo M
- Issue date: 2024 Jul
- Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy.
- Authors: Ragavan M, Das M
- Issue date: 2020 Jun 29
- Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study.
- Authors: Senan S, Okamoto I, Lee GW, Chen Y, Niho S, Mak G, Yao W, Shire N, Jiang H, Cho BC
- Issue date: 2020 Mar